Nuclear Medicine Program progress report, quarter ending March 31, 1992

Technical Report · Wed Jul 01 04:00:00 EDT 1992

DOI:https://doi.org/10.2172/10159077· OSTI ID:10159077

Knapp, Jr, F F; Ambrose, K R; Callahan, A P; McPherson, D W; Mirzadeh, S; Hasan, A; Lambert, C R; Rice, D E

We describe the design synthesis and initial animal testing of a new iodine-131-labeled triglyceride analogue for the potential evaluation of clinical pancreatic insufficiency. The new agent is 1,2-dipalmitoyl-3-[(15-p-iodophenyl)pentadecanoyl] rac-glycerol(1,2-Pal-3-IPPA). Following oral administration of the iodine-125-labeled agent to rats, 34.5+8.8% of the administered activity was excreted in the urine within one day, demonstrating that radioiodinated IPPA is absorbed in the intestine after release from the triglyceride by pancreatic lipase. The final catabolic product of IPPA is then conjugated and excreted via the urinary bladder. Urine analysis following oral administration of this new agent to patients may thus be a new, simple method for the clinical evaluation of various gastrointestinal diseases. The synthesis and the initial biological evaluation of the 3R-isomer of [{sup 125}I]IQNP are also described.

• Research Organization: Oak Ridge National Lab., TN (United States)
• Sponsoring Organization: USDOE, Washington, DC (United States)
• DOE Contract Number: AC05-84OR21400
• OSTI ID: 10159077
• Report Number(s): ORNL/TM--12110; ON: DE92017142
• Country of Publication: United States
• Language: English

Related Subjects

38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEAR CHEMISTRY
400703
550601
62 RADIOLOGY AND NUCLEAR MEDICINE
CHEMICAL PREPARATION
DIAGNOSIS
DISEASES
ENZYME ACTIVITY
EXCRETION
IODINE 125
LABELLED COMPOUNDS
LIPASES
METABOLISM
NUCLEAR MEDICINE
PANCREAS
PROGRESS REPORT
RADIOISOTOPE PRODUCTION
RATS
TRIGLYCERIDES
UNSEALED RADIONUCLIDES IN DIAGNOSTICS
URINE